Why go beyond a 1st dose?
Breakthrough varicella is an ongoing concern^a

aBreakthrough infection was defined as any case  of varicella occuring >42 days postvaccination.1	Abdomen of child with breakthrough varicella lesions. (Reprinted with permission from the CDC.)

• Varicella outbreaks pose a threat to those who are at high risk for severe disease and have contraindications for vaccination.⁸
• Varicella outbreaks can cause disruptions for students, teachers, parents, and public health authorities.⁸

Varicella is the most frequently reported disease for which there is a vaccine available in the United States⁹

• Over 48,000 cases were reported nationwide in 2006.⁹

Select Safety Information

VARIVAX is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactoid reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems; an immunodeficient condition or receiving immunosuppressive therapy; active, untreated tuberculosis; active febrile illness; or those who are pregnant.

In children, adolescents, and adults monitored for up to 42 days, the adverse effects most frequently reported were as follows: fever, injection-site complaints, varicella-like rash (injection site), and varicella-like rash (generalized).

The duration of protection of VARIVAX is unknown; however, long-term efficacy studies have demonstrated continued protection up to 10 years after vaccination.

Vaccination with VARIVAX may not result in protection of all healthy, susceptible children, adolescents, and adults.

Before administering VARIVAX, please read the Prescribing Information and
Patient Product Information.

VARIVAX is a registered trademark of Merck & Co., Inc.